Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Arthritis Rheumatol. 2020 Dec 26;73(2):315–323. doi: 10.1002/art.41493

Table 1.

Demographics and SSc Characteristics comparing patients with a history of cancer to those who have never had a cancer. Patients with cancer history are more likely to be Caucasian, older at SSc onset, and have a higher Modified Rodnan Skin Score (MRSS).

Patient Characteristics No History of Cancer (N=401) *Cancer History (N=309) p-value
n (%) / median (IQR) n (%) / median (IQR)

Sex 345 (86) 254 (82) 0.1760
Hispanic Ethnicity 18 (9) 3 (2) 0.0020
Race
 Caucasian 292 (73) 277 (89) <0.0001
 African American 81 (20) 23 (7)
History of smoking (ever) 185 (47) 161 (52) 0.1490
Age at SSc-symptom onset (RP or non-RP) (IQR) 39.5 (28–49) 48.2 (38–58) <0.0001
Meets ACR 2013 Criteria 387 (97) 300 (97) 1.0000
Follow-up Duration (yrs) 14.4 (9–24) 12.6 (6–23) 0.0969
Disease Duration Upon Cohort Entry 6.5 (2.6–15) 4.9 (1.5–15) 0.0740
Cutaneous Subtype
 Sine 13 (3) 9 (3) 0.2730
 Limited 214 (53) 144 (46)
 Type II Skin 36 (9) 33 (11)
 Diffuse 138 (34) 124 (40)
Cutaneous Subtype (limited vs diffuse) 138 (34) 124 (40) 0.1170
Maximum Modified Rodnan Skin Score 6 (3–17) 9 (4–20) 0.0030
History of scleroderma renal crisis 16 (4) 19 (6) 0.2220
Minimum FVC % predicted over follow-up (n=668/710) 70 (54–84) 70 (57–84) 1.0000
Maximum Right Ventricular Systolic Pressure (n=590/710) 37 (32–50) 40 (33–53) 0.0700
Pulmonary Hypertension (mean PAP>20) (n=148) 60 (15) 41 (13) 0.5880
Pulmonary Hypertension (mean PAP>24) (n=148) 54 (13) 37 (12) 0.5730
Presence of baseline TFR 35 (9) 41 (13) 0.0660
Presence of synovitis on any exam 84 (21) 68 (22) 0.7820
Deceased 124 (31) 131 (44) 0.0010
Serology
 Any ThTo Component (hPOP1, RPP25 RPP30, or RPP40) 36 (9) 23 (7) 0.4950
 hPOP1 36 (9) 22 (7) 0.4090
 RPP25 23 (6) 12 (4) 0.2970
 RPP30 24 (6) 20 (6) 0.8760
 RPP40 31 (8) 23 (7) 1.0000

RP=Raynaud’s phenomenon, SSc=systemic sclerosis, TFR=tendon friction rubs.

*

Excluding non-melanotic skin cancers